High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback